Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
SEC Accession No. 0001479290-22-000069
Filing Date
2022-05-13
Accepted
2022-05-13 18:14:38
Documents
1
Period of Report
2022-05-04

Document Format Files

Seq Description Document Type Size
1 FORM 4/A wf-form4a_165248002605949.html 4/A  
1 FORM 4/A wf-form4a_165248002605949.xml 4/A 4470
  Complete submission text file 0001479290-22-000069.txt   5843
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Issuer) CIK: 0001479290 (see all company filings)

EIN.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 2525 DUPONT DRIVE IRVINE CA 92612
Business Address
Gangolli Julian S (Reporting) CIK: 0001532023 (see all company filings)

Type: 4/A | Act: 34 | File No.: 001-36297 | Film No.: 22924438